CROI 2026: i-Base reports from this essential meeting
13 March 2026. Related: Conference reports, CROI 33 (Retrovirus) 2026.
Simon Collins, HIV i-Base
The following reports are from the recent CROI 2026 conference held in Denver from 22 to 25 February,
Further reports will be added weekly to the list below.
GLP-1 studies of weight loss drugs included short-term impact in a real world setting, potential benefits on reducing smoking, cardiovascular risk, depression, and liver fibrosis with the oral abstract on the potential to perhaps reverse the gut damage that occurs in very early HIV infection and that persists despite effective ART. Still lots of gaps in data though.
A new once-daily pill can effectively simplify ART for many on complicated combinations. This is a tiny pill – smaller than Biktarvy – and let many people stop boosted PIs – or other complex combinations used by older people who have been on ART for more than 20 years.
This new study is the second randomised clinical trial to report no benefit against gonorrhoea for gay men given the 4CMenB vaccine. Many questions for why these results are so different to observational studies and generated a lot of discussions and questions.
This phase 3 study showed that a new oral drug called pritelivir can work in people who have drug resistance to other herpes treatments. Available now in an expanded access programme while being reviewed by the FDA.
Long-term results from this 8-year French PrEP study in predominantly gay men continued to show efficacy of 2:1:1 dosing and the flexibility to switch to daily dosing and back depending on your circumstances.
Analysis of the impact of last year’s US policies – and inspiring strategies for how to overcome them this year. The talk drew on the unique and dynamic history of ACT-UP to give us strength and hope for the future, when the current US administration will be replaced..
The study looking as dose selection for this very exciting option for once-monthly oral PrEP.
An interesting study by independent investigators looking at this now discontinued PrEP drug against HIV with drug resistance. Luckily, this is unlikely to affect the new replacement compound MK-8527.
A statement by the conference organiser’s reflects the concerns of researchers to the current anti-science policies of the Trump administration. It is shocking that organises needed to do this but very important that they did.
An early overview covering new HIV drugs, new PrEP drugs, bNAbs, HIV complications, GLP-1 weight-busting drugs in people with HIV, cure-related research, key populations, the impact of US policy changes, new monitoring testa and more.